Circulating tumor DNA clearance as a trial-level early efficacy signal in solid tumors: a systematic review and meta-analysis of randomized trials.
Early drops in circulating tumor DNA during treatment predict long-term survival, potentially speeding up drug approval and reducing trial costs.
This meta-analysis demonstrates that ctDNA clearance during early treatment cycles correlates robustly with survival outcomes at the trial level across solid tumor types, supporting its use as an early efficacy endpoint in clinical trials. Validation of ctDNA clearance as a surrogate endpoint could accelerate drug approval timelines and reduce trial costs.
What the study was
- Study design
- Meta-analysis (trial-level endpoint surrogacy analysis)
- Population
- Solid tumor patients in clinical trials
- Category
- Early Detection
- Maturity
- Validated
- Journal
- Translational cancer research
Why it surfaced
Trial-level validation of ctDNA clearance as a surrogate efficacy endpoint with broad applicability across solid tumors; directly impacts clinical trial design and drug development.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.